

NOVAVAX INC
Form 8-K
May 14, 2003

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT UNDER SECTION 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 13, 2003

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

0-26770

(Commission
File No.)

22-2816046

(I.R.S. Employer
Identification No.)

8320 Guilford Road, Columbia, MD

(Address of principal executive offices)

21046

(Zip code)

(301) 854-3900

Registrant's telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

**NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT**

ITEM 7. EXHIBITS.

99.1 Press Release dated May 13, 2003.

ITEM 9. REGULATION FD DISCLOSURE. (The following disclosure is also furnished under Item 12. Results of Operations and Financial Condition .)

In accordance with SEC Release No. 33-8216, the following information is furnished under Item 12. Results of Operations and Financial Condition , and is furnished under Item 9. Regulation FD Disclosure .

On May 13, 2003, Novavax, Inc. (Novavax or the Company) reported its first quarter earnings for 2003.

A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVAVAX, INC.

Date: May 13, 2003

By: /s/ Dennis W. Genge

Dennis W. Genge, Vice President and Chief
Financial Officer/Treasurer